Hubert R. Wirtz
Expertise in
8
conditions

Hubert R. Wirtz

Leipzig, SN, DE 
Expertise in
8
conditions
Leipzig, SN, DE 

Overview

Hubert Wirtz practices practicing medicine in Leipzig, Germany.

Mr. Wirtz is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Respiratory Acidosis, Pulmonary Hypertension, Pulmonary Fibrosis, Acute Interstitial Pneumonia, and Lung Transplant.

He is actively involved in clinical research, co-authoring 123 peer reviewed articles and participating in 9 clinical trials.

Gender

Male

Locations

Leipzig, SN, Germany
Other Locations
Bonn, NW, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel To Dostarlimab + Docetaxel To Docetaxel Alone In Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed On Prior Anti-PD-(L)1 Therapy And Chemotherapy (COSTAR Lung)
A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel To Dostarlimab + Docetaxel To Docetaxel Alone In Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed On Prior Anti-PD-(L)1 Therapy And Chemotherapy (COSTAR Lung)
Enrollment Status: Active_not_recruiting
Publish Date: July 01, 2026
Intervention Type: Biological, Drug
Study Drugs: Cobolimab, Dostarlimab, Docetaxel
Study Phase: Phase 2/Phase 3
Advancing Brigatinib Properties in Anaplastic Lymphoma Kinase Positive Non-small Cell Lung Cancer (ALK+ NSCLC) Patients
Advancing Brigatinib Properties in Anaplastic Lymphoma Kinase Positive Non-small Cell Lung Cancer (ALK+ NSCLC) Patients
Enrollment Status: Completed
Publish Date: June 23, 2026
Intervention Type: Drug
Study Drugs: Brigatinib, Tyrosine kinase inhibitor
Study Phase: Phase 2
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
Enrollment Status: Completed
Publish Date: June 16, 2026
Intervention Type: Drug
Study Drug: Ralinepag
Study Phase: Phase 3
A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) as a Single Agent and In Combination With Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC) (RAMP 202)
A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) as a Single Agent and In Combination With Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC) (RAMP 202)
Enrollment Status: Completed
Publish Date: January 12, 2024
Intervention Type: Drug
Study Drugs: VS-6766, VS-6766+Defactinib
Study Phase: Phase 2
Investigating Significant Health Trends in IPF (INSIGHTS-IPF). Nationwide Prospective Registry.
Investigating Significant Health Trends in IPF (INSIGHTS-IPF). Nationwide Prospective Registry.
Enrollment Status: Completed
Publish Date: July 27, 2022
Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
Enrollment Status: Completed
Publish Date: June 02, 2022
Intervention Type: Drug
Study Drug: UT-15C
Study Phase: Phase 3
A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy
A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy
Enrollment Status: Completed
Publish Date: February 13, 2020
Intervention Type: Drug
Study Phase: Phase 3
Effectiveness of TNI (Nasal High-flow) vs. BiPAP (Biphasic Positive Airway Pressure) in Chronic Global Insufficiency in COPD (Chronic Obstructive Pulmonary Disease) Patients
Effectiveness of TNI (Nasal High-flow) vs. BiPAP (Biphasic Positive Airway Pressure) in Chronic Global Insufficiency in COPD (Chronic Obstructive Pulmonary Disease) Patients
Enrollment Status: Completed
Publish Date: November 15, 2018
Intervention Type: Device
Study Phase: Not Applicable
View 7 Less Clinical Trials

123 Total Publications

Short-term culture of human endoscopic specimens for the study of chronic inflammation.
Short-term culture of human endoscopic specimens for the study of chronic inflammation.
Journal: Methods in cell biology
Published: September 03, 2026

Frequently Asked Questions about Hubert R. Wirtz

Is Hubert R. Wirtz a top-rated expert for Respiratory Acidosis?

MediFind is an objective health platform that identifies experts based on real-world data. Hubert R. Wirtz is classified as an Advanced expert for Respiratory Acidosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Hubert R. Wirtz participate in research or clinical trials?

Yes. Hubert R. Wirtz has published 123 articles and abstracts on conditions like Respiratory Acidosis. You can view a list of Hubert R. Wirtz's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Wirtz's expertise for a condition
ConditionClose
      View All 8 Advanced Conditions
      View All 24 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile